Evogene (EVGN)

Currency in ILS
208.8
+2.5(+1.21%)
Closed·
EVGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
203.0212.0
52 wk Range
193.21,085.0
Key Statistics
Bid/Ask
226.80 / 171.80
Prev. Close
206.3
Open
206.3
Day's Range
203-212
52 wk Range
193.2-1,085
Volume
19.6K
Average Volume (3m)
28.93K
1-Year Change
-51.3627%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Evogene News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Evogene Earnings Call Summary for Q1/2026

  • Evogene Q1 2026 revenue plunged 87% YoY to $0.3M; net loss widened 97% to $5.9M from reduced Casterra seed sales and seasonal factors.
  • Stock rose 1.95% to $204.8 despite losses as investors backed strategic pivot to ChemPass AI platform for pharma and agriculture applications.
  • Cash position at $13.1M as of March 31, 2026; company projects continued losses but anticipates revenue growth from new partnerships.
  • CEO Haviv emphasized ChemPass AI positioning in pharmaceutical and agricultural sectors; new collaborations announced to drive drug discovery innovation.
  • Key risks include revenue decline persistence, warrant accounting volatility, and heavy dependence on successful integration of new collaborations.
Last Updated: 2026/05/20, 19:58
Read Full Transcript

Earnings

Latest Release
Mar 05, 2026
EPS / Forecast
-0,61 / --
Revenue / Forecast
314K / --
EPS Revisions
Last 90 days

EVGN Income Statement

Compare EVGN to Peers and Sector

Metrics to compare
EVGN
Peers
Sector
Relationship
P/E Ratio
−0.4x−2.0x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
−2.9x1.3x2.6x
Price / LTM Sales
4.0x5.8x3.1x
Upside (Analyst Target)
-669.3%52.5%
Fair Value Upside
Unlock17.1%6.0%Unlock

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
33,08K0,32%68,24K
Other Institutional Investors
527,31K5,06%1,09M
Public Companies & Retail Investors
9,85M94,62%20,33M
Total
10,41M100,00%21,48M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Migdal Mutual Funds - MTF TR (4A) TA-Growth IL0,21%22 26046
P & S Renditefonds0,10%10 00021

FAQ

What Is the Evogene (EVGN) Stock Price Today?

The Evogene stock price today is 208,8 ILS.

What Stock Exchange Does Evogene Trade On?

Evogene is listed and trades on the Tel Aviv Stock Exchange.

What Is the Stock Symbol for Evogene?

The stock symbol for Evogene is "EVGN."

What Is the Evogene Market Cap?

As of today, Evogene market cap is 21,74M ILS.

What Is Evogene's Earnings Per Share (TTM)?

The Evogene EPS (TTM) is -2,2.

From a Technical Analysis Perspective, Is EVGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Evogene Stock Split?

Evogene has split 2 times.

How Many Employees Does Evogene Have?

Evogene has 52 employees.

What is the current trading status of Evogene (EVGN)?

As of May 26, 2026, Evogene (EVGN) is trading at a price of 208,8 ILS, with a previous close of 206,3 ILS. The stock has fluctuated within a day range of 203,0 ILS to 212,0 ILS, while its 52-week range spans from 193,2 ILS to 1 085,0 ILS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.